Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL LANZ

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1710034129
CMS profile
349521
Location
CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$196,802.24

209 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL LANZ

NPI 1710034129 · CMS profile ID 349521

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710034129?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL LANZ, NPI 1710034129, CMS profile ID 349521. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710034129?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MIGUEL LANZ, NPI 1710034129, CMS profile ID 349521. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710034129?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MIGUEL LANZ, NPI 1710034129, CMS profile ID 349521, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1710034129?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

209 matching records · $196,802.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 209 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 209.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech, Inc. $54.4605/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211552641 CMS
Regeneron Healthcare Solutions, Inc. $91.6505/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212970043 CMS
Regeneron Healthcare Solutions, Inc. $135.7805/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212970045 CMS
GENZYME CORPORATION $24.6405/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233312656 CMS
Genentech USA, Inc. $128.0805/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211552626 CMS
Regeneron Healthcare Solutions, Inc. $38.6705/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212970041 CMS
AstraZeneca Pharmaceuticals LP $134.0005/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206598826 CMS
Regeneron Healthcare Solutions, Inc. $17.5005/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212970037 CMS
Regeneron Healthcare Solutions, Inc. $341.6005/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212970039 CMS
Regeneron Pharmaceuticals, Inc. $316.5005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239981 CMS
Regeneron Pharmaceuticals, Inc. $1,266.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239983 CMS
Regeneron Pharmaceuticals, Inc. $1,266.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239985 CMS
Regeneron Pharmaceuticals, Inc. $316.5005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239987 CMS
Regeneron Pharmaceuticals, Inc. $158.2505/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239989 CMS
Regeneron Pharmaceuticals, Inc. $633.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213239991 CMS
AstraZeneca Pharmaceuticals LP $3,750.0005/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207012686 CMS
Genentech USA, Inc. $114.5505/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211552634 CMS
AstraZeneca Pharmaceuticals LP $4,300.0004/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206526138 CMS
AstraZeneca Pharmaceuticals LP $3,200.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206622962 CMS
Novartis Pharmaceuticals Corporation $34.9304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200604746 CMS
Regeneron Healthcare Solutions, Inc. $257.6004/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212970035 CMS
AstraZeneca Pharmaceuticals LP $1,600.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206953763 CMS
AstraZeneca Pharmaceuticals LP $4,300.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1207050261 CMS
Regeneron Healthcare Solutions, Inc. $6,647.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212970033 CMS
AstraZeneca Pharmaceuticals LP $5.9904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206157826 CMS
AstraZeneca Pharmaceuticals LP $403.5304/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206468774 CMS
AstraZeneca Pharmaceuticals LP $426.3804/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206643191 CMS
AstraZeneca Pharmaceuticals LP $20.0804/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206798617 CMS
AstraZeneca Pharmaceuticals LP $45.8004/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206956175 CMS
AstraZeneca Pharmaceuticals LP $120.8504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207299366 CMS
AstraZeneca Pharmaceuticals LP $17.4804/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206316591 CMS
AstraZeneca Pharmaceuticals LP $145.6004/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1207087131 CMS
GENZYME CORPORATION $138.2404/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233312632 CMS
GENZYME CORPORATION $3,482.0004/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233312634 CMS
GENZYME CORPORATION $309.6904/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233312636 CMS
GENZYME CORPORATION $5.3004/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233312638 CMS
GENZYME CORPORATION $20.0004/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233312640 CMS
GENZYME CORPORATION $175.0004/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233312642 CMS
AstraZeneca Pharmaceuticals LP $342.3904/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206241632 CMS
AstraZeneca Pharmaceuticals LP $14.0504/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206444122 CMS
AstraZeneca Pharmaceuticals LP $121.8404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206768708 CMS
AstraZeneca Pharmaceuticals LP $320.6004/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1206991167 CMS
AstraZeneca Pharmaceuticals LP $25.7504/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207204116 CMS
GENZYME CORPORATION $6.2904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233312646 CMS
GENZYME CORPORATION $173.6004/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233312648 CMS
GENZYME CORPORATION $32.5004/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233312650 CMS
GENZYME CORPORATION $5,381.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233312652 CMS
Regeneron Healthcare Solutions, Inc. $189.2804/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212970029 CMS
Regeneron Healthcare Solutions, Inc. $121.8404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212970031 CMS
AstraZeneca Pharmaceuticals LP $3,750.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206738442 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59,294.90 110
PY2020 $27,545.29 47
PY2021 $110,436.66 139
PY2022 $102,971.84 125
PY2023 $107,983.37 169
PY2024 $172,817.40 174
PY2025 $196,802.24 209

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $183,409.80 5
PY2025 Principal investigator $110,989.77 139
PY2024 Recipient $53,984.70 2
PY2024 Principal investigator $140,441.36 128
PY2023 Principal investigator $117,776.77 47
PY2022 Principal investigator $133,090.56 24
PY2021 Principal investigator $33,539.35 7
PY2020 Principal investigator $46,643.19 5
PY2019 Recipient $18,627.98 4
PY2019 Principal investigator $11,446.13 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 11/17/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184261577
Principal investigator 1 Genentech, Inc. $85,581.60 10/09/2025 Non-covered Recipient Entity
AAADRS CLINICAL RESEARCH CENTER
eNO in OFC & OMA Rx in FA No dispute reported 06/30/2026 1211566190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 10/03/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184245597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 10/03/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184245599
Recipient Regeneron Pharmaceuticals, Inc. $1,459.29 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 06/18/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 06/18/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 06/18/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 05/19/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 05/19/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 05/19/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 05/19/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $212.50 05/19/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196331
Recipient Genentech, Inc. $149,176.75 05/08/2025 Covered Recipient Physician eNO in OFC & OMA Rx in FA No dispute reported 06/30/2026 1211537860
Recipient Genentech, Inc. $7,843.06 05/06/2025 Covered Recipient Physician eNO in OFC & OMA Rx in FA No dispute reported 06/30/2026 1211537863
Recipient Regeneron Pharmaceuticals, Inc. $937.50 05/01/2025 Covered Recipient Physician ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184119405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 04/04/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184181710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.00 03/06/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184157791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $212.50 02/27/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184156062
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,890.63 02/24/2025 Non-covered Recipient Entity
LANZ, MIGUEL, OFFICE
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185555065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 02/17/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154138
Recipient Genentech, Inc. $23,993.20 01/21/2025 Covered Recipient Physician eNO in OFC & OMA Rx in FA No dispute reported 06/30/2026 1211537856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 01/15/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184147531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 01/15/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184147533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 01/15/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184147535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $610.94 01/02/2025 Non-covered Recipient Entity
MIGUEL J LANZ MD AAADRS CLINICAL RESEARCH CENTER
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144352